keyword
MENU ▼
Read by QxMD icon Read
search

Savor

keyword
https://www.readbyqxmd.com/read/28622738/assessment-of-the-risk-of-hospitalization-for-heart-failure-with-dipeptidyl-peptidase-4-inhibitors-saxagliptin-alogliptin-and-sitagliptin-in-patients-with-type-2-diabetes-using-an-alternative-measure-to-the-hazard-ratio
#1
Masayuki Kaneko, Mamoru Narukawa
BACKGROUND: Saxagliptin statistically significantly increased the risk of hospitalization for heart failure compared with placebo in the clinical trial of SAVOR-TIMI 53. Neither the reason why only saxagliptin among several dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk, nor the clinical implication of the result has been explained. OBJECTIVE: To evaluate the risk of hospitalization for heart failure associated with DPP-4 inhibitors by using an alternative measure to the hazard ratio...
July 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28572599/comparisons-of-microvascular-and-macrovascular-changes-in-aldosteronism-related-hypertension-and-essential-hypertension
#2
Monica Varano, Pierluigi Iacono, Massimiliano M Tedeschi, Claudio Letizia, Mario Curione, Claudio Savoriti, Erika Baiocco, Laura Zinnamosca, Cristiano Marinelli, Barbara Boccassini, Mariacristina Parravano
Case-control observational study to evaluate the microvascular and macrovascular changes in patients with hypertension secondary to primary aldosteronism (PA), essential hypertension (EH) and healthy subjects. Measurements of arterial stiffness including augmentation index (AIx) and pulse wave velocity (PWV) were assessed using a TensioClinic arteriograph system. Retinal microcirculation was imaged by a Retinal Vessel Analyzer (RVA) and a non-midriatic camera (Topcon-TRC-NV2000). IMEDOS software analyzed the retinal artery diameter (RAD), retinal vein diameters (RVD) and arteriole-to-venule ratio (AVR) of the vessels coming off the optic disc...
June 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28554140/health-related-quality-of-life-implications-of-cardiovascular-events-in-individuals-with-type-2-diabetes-mellitus-a-subanalysis-from-the-saxagliptin-assessment-of-vascular-outcomes-recorded-in-patients-with-diabetes-mellitus-savor-timi-53-trial
#3
Andrew H Briggs, Deepak L Bhatt, Benjamin M Scirica, Itamar Raz, Karissa M Johnston, Shelagh M Szabo, Klas Bergenheim, Jayanti Mukherjee, Boaz Hirshberg, Ofri Mosenzon
BACKGROUND: The impact of cardiovascular complications on health-related quality-of-life (HRQoL) in type 2 diabetes mellitus has not been clearly established. Using EQ5D utility data from SAVOR-TIMI 53, a large phase IV trial of saxagliptin versus placebo, we quantified the impact of cardiovascular and other major events on HRQoL. METHODS: EQ5D utilities were recorded annually and following myocardial infarction (MI) or stroke. Utilities among patients experiencing major cardiovascular events were analyzed using linear mixed-effects regression, adjusting for baseline characteristics (including EQ5D utility), and compared to those not experiencing major cardiovascular events...
January 23, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28459046/dipeptidyl-peptidase-4-inhibitors-and-the-risk-of-heart-failure-a-systematic-review-and-meta-analysis
#4
Subodh Verma, Ronald M Goldenberg, Deepak L Bhatt, Michael E Farkouh, Adrian Quan, Hwee Teoh, Kim A Connelly, Lawrence A Leiter, Jan O Friedrich
BACKGROUND: Given recent discrepant results from randomized controlled trials (RCTs), we examined the totality of RCT evidence assessing the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and heart failure. METHODS: MEDLINE, Embase and ClinicalTrials.gov were searched without language restrictions to August 2016 for RCTs comparing DPP-4 inhibitors to placebo or no therapy for a period of 24 weeks or more. We included all heart failure outcomes when listed either as a serious adverse event or adverse event...
January 2017: CMAJ Open
https://www.readbyqxmd.com/read/28432754/intraclass-differences-in-the-risk-of-hospitalisazion-for-heart-failure-among-type-2-diabetic-patients-initiating-a-dipeptydil-peptidase-4-inhibitor-or-a-sulphonylurea-results-from-the-osmed-health-db-registry
#5
Gian Paolo Fadini, Stefania Saragoni, Pierluigi Russo, Luca Degli Esposti, Saula Vigili de Kreutzenberg, Mario Melazzini, Angelo Avogaro
AIMS: Heart failure (HF) is frequent in type 2 diabetes (T2D) and several glucose-lowering medications may increase HF risk. In the SAVOR-TIMI trial, patients on Saxagliptin experienced a 27% higher risk of hospitalisation for HF (HHF). In a retrospective study on 127,555 patients, we showed that DPP-4i therapy was associated with a lower HHF risk than sulphonylurea (SU) therapy. We herein re-analyzed such data to evaluate intraclass differences among DPP-4i and SU. MATERIALS AND METHODS: We included T2D patients initiating DPP-4i or SU alone or in combination with metformin...
April 21, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28431666/glp-1-receptor-agonists-and-heart-failure-in-diabetes
#6
André J Scheen
The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones (glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR - TIMI 53), whereas a markedly decreased risk was highlighted with the sodium - glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin in EMPA-REG OUTCOME...
April 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28417296/dpp4-inhibitors-and-cardiovascular-outcomes-safety-on-heart-failure
#7
REVIEW
Chang Xia, Aditya Goud, Jason D'Souza, CHanukya Dahagam, Xiaoquan Rao, Sanjay Rajagopalan, Jixin Zhong
Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes...
April 18, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28414476/a-socio-cultural-instrumental-approach-to-emotion-regulation-culture-and-the-regulation-of-positive-emotions
#8
Xiaoming Ma, Maya Tamir, Yuri Miyamoto
We propose a sociocultural instrumental approach to emotion regulation. According to this approach, cultural differences in the tendency to savor rather than dampen positive emotions should be more pronounced when people are actively pursuing goals (i.e., contexts requiring higher cognitive effort) than when they are not (i.e., contexts requiring lower cognitive efforts), because cultural beliefs about the utility of positive emotions should become most relevant when people are engaging in active goal pursuit...
April 17, 2017: Emotion
https://www.readbyqxmd.com/read/28402902/cardiovascular-outcome-studies-with-incretin-based-therapies-comparison-between-dpp-4-inhibitors-and-glp-1-receptor-agonists
#9
REVIEW
André J Scheen
Dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent two distinct classes of incretin-based therapies used for the treatment of type 2 diabetes. Non-inferiority versus placebo was shown in large prospective cardiovascular outcome trials in patients with high cardiovascular risk: SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin); ELIXA (lixisenatide), LEADER (liraglutide) and SUSTAIN 6 (semaglutide). The promises raised by meta-analyses of phase 2-3 trials with DPP-4is were non confirmed as no cardiovascular protection could be evidenced...
May 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28380722/effects-of-a-savoring-intervention-on-resilience-and-well-being-of-older-adults
#10
Jennifer L Smith, Agnieszka A Hanni
Savoring is the ability to be mindful of positive experiences and to be aware of and regulate positive feelings about these experiences. Previous research has found that savoring interventions can be effective at improving well-being of younger adults, but findings have not been extended to older populations. This pilot study examined the effects of a 1-week savoring intervention on older adults' psychological resilience and well-being (i.e., depressive symptoms and happiness). Participants, 111 adults ages 60 or over, completed measures of resilience, depressive symptoms, and happiness pre- and postintervention as well as 1 month and 3 months after the intervention...
February 1, 2017: Journal of Applied Gerontology: the Official Journal of the Southern Gerontological Society
https://www.readbyqxmd.com/read/28341488/what-would-be-the-fate-of-the-association-between-saxagliptin-and-heart-failure-admission-in-the-savor-timi-53-trial-if-appropriate-statistical-methods-should-have-been-applied
#11
Ana María Cebrián-Cuenca, Eduardo Núñez, Julio Núñez-Villota, Luciano Consuegra-Sánchez
No abstract text is available yet for this article.
March 9, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28284632/saxagliptin-and-heart-failure-in-the-savor-timi-53-trial-reflections-on-the-bradford-hill-criteria
#12
Ana M Cebrián Cuenca, Domingo Orozco Beltrán, Jorge Navarro Pérez, Fernando Álvarez-Guisasola, Julio Núñez Villota, Luciano Consuegra-Sánchez
No abstract text is available yet for this article.
March 8, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28249585/incretin-based-agents-in-type-2-diabetic-patients-at-cardiovascular-risk-compare-the-effect-of-glp-1-agonists-and-dpp-4-inhibitors-on-cardiovascular-and-pancreatic-outcomes
#13
Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao, Junhui Xie, Yan Yang, Xuefeng Yu
BACKGROUND: Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different effect on cardiovascular (CV) outcomes. The present study is to evaluate and compare effects of incretin-based agents on CV and pancreatic outcomes in patients with type 2 diabetes mellitus (T2DM) and high CV risk. METHODS: Six prospective randomized controlled trials (EXMAINE, SAVOR-TIMI53, TECOS, ELIXA, LEADER and SUSTAIN-6), which included three trials for DPP-4Is and three trials for GLP-1As, with 55,248 participants were selected to assess the effect of different categories of incretin-based agents on death, CV outcomes (CV mortality, major adverse CV events, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization), pancreatic events (acute pancreatitis and pancreatic cancer) as well as on hypoglycemia...
March 1, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28199026/secure-base-script-content-explains-the-association-between-attachment-avoidance-and-emotion-related-constructs-in-parents-of-young-children
#14
Jessica L Borelli, Margaret L Burkhart, Hannah F Rasmussen, Robin Brody, David A Sbarra
The secure base script (SBS) framework is one method of assessing implicit internal working models of attachment; recently, researchers have applied this method to analyze narratives regarding relationship experiences. This study examines the associations between attachment avoidance and SBS content when parents recall a positive moment of connection between themselves and their children (relational savoring) as well as their association with parental emotion and reflective functioning (RF). Using a sample of parents (N = 155, 92% female) of young children (53% boys, Mage = 12...
March 2017: Infant Mental Health Journal
https://www.readbyqxmd.com/read/28181728/hypoglycaemia-manifestations-and-recurrent-events-lessons-from-the-savor-timi-53-outcome-study
#15
Avivit Cahn, Ofri Mosenzon, Deepak L Bhatt, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Christina Stahre, KyungAh Im, Estella Kanevsky, Itamar Raz
Hypoglycaemia is a well-known risk associated with the use of sulphonylureas and insulin, often limiting achievement of glycaemic goals. Recognizing the precipitants and recurrence patterns of hypoglycaemic events, particularly major events, is therefore clinically important. The SAVOR-TIMI-53 trial was a cardiovascular outcome study of 16 492 patients allocated to saxagliptin vs placebo added to conventional care for a median of 2.1 years. Hypoglycaemic events were a prespecified outcome in the study and were defined as a symptomatic episode that recovered with carbohydrates or any recorded blood glucose <3...
February 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28156630/emotional-disclosure-in-home-hospice-cancer-care-implications-for-spouse-caregiver-bereavement
#16
Lee Ellington, Margaret Clayton, Michael Caserta, Dale Lund, Kathi Mooney
54 Background: Evidence shows the benefit of positive and negative emotional disclosure for family caregivers (CG), but little is known about the impact of emotional disclosure at end of life. We assessed the effect of CG and hospice nurse disclosure during home visits on CG anxiety and depression in bereavement. METHODS: As part of a larger study, nurse visits to 95 spouse CGs of cancer home hospice patients were audio recorded. An adapted Roter Interaction Analysis System was used to identify emotional disclosure: CG and nurse positive emotion (humor, gratitude), CG distress, and nurse emotional response (reassurance, validation)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28122713/diabetes-hypertension-and-chronic-kidney-disease-progression-role-of-dpp4
#17
Ravi Nistala, Virginia Savin
The protein dipeptidyl peptidase 4 (DPP4) is a target in diabetes management and reduction of associated cardiovascular risk. Inhibition of the enzymatic function and genetic deletion of DPP4 is associated with tremendous benefits to the heart, vasculature, adipose tissue, and the kidney in rodent models of obesity, diabetes and hypertension, and associated complications. The recently concluded, "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53" trial revealed a reduction in proteinuria in chronic kidney disease patients (stages 1-3)...
April 1, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28121469/savor-timi-to-sustain-6-a-critical-comparison-of-cardiovascular-outcome-trials-of-antidiabetic-drugs
#18
REVIEW
Awadhesh Kumar Singh, Ritu Singh
Since the inception of mandatory cardiovascular (CV) safety outcome trial (CVOT) promulgated by US FDA in 2008, seven trials have so far been published with three different classes of antidiabetic drugs in type 2 diabetes mellitus (T2DM). This mini-review aims to critically analyse these CVOTs in terms of different outcomes achieved. Areas covered: An electronic search pertaining to the subject was conducted till September 2016. The three CVOT conducted with saxagliptin, alogliptin and sitagliptin respectively, found them to be CV-neutral...
April 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27797925/effect-of-saxagliptin-on-renal-outcomes-in-the-savor-timi-53-trial
#19
Ofri Mosenzon, Gil Leibowitz, Deepak L Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M Scirica, Itamar Raz
OBJECTIVE: Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy. RESEARCH DESIGN AND METHODS: We studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to saxagliptin versus placebo and followed for a median of 2.1 years in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. RESULTS: At baseline, 9,696 (58...
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27796922/schizophrenia-reaction-to-positive-life-events
#20
REVIEW
Mary V Seeman
Negative life events can exacerbate symptoms in schizophrenia, but there is no literature on the effect on psychotic symptoms of positive life events. The purpose of this review was to scan the literature that studies how the joy that accompanies positive life events can be dampened and dismissed or, alternatively, savored and maintained, and how this contrast applies to schizophrenia. A literature search elicited 53 articles relevant to schizophrenia. Schizophrenia was found to be linked with difficulties in the processing of reward, in feeling that one was deserving of a reward, in sharing news of positive events, in knowing with whom to share, in knowing how to elicit a positive response from listeners when communicating good news, and in ensuring that positive feelings endure...
October 29, 2016: Psychiatric Quarterly
keyword
keyword
50754
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"